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Abstract
Objective: To finding out the change of weight and body 
mass index (BMI) of single rodlevonorgestrel implant 
acceptor (Monoplant®).
Methods: A cross-sectional descriptive study was 
conductedusing data changes of weight and BMI obtained 
from series of measurement which is recorded in patients’ 
medical record in three years of Monoplant® placement 
in Raden Saleh Clinic, Jakarta. This method is the part of a 
research of a bigger phase two in clinical test.
Results: From 21 subjects of this research, the average weight 
and BMI before and after 3 years of Monoplant® placement 
is gained, i.e. 53.1 (SD 11,0) kg and 22.4 (SD 4.5) kg/m2, 
and 54.8 (SD 9.4) kg and 23.1 (SD 3.9) kg/m2. Despite the 
tendency of increasing, statistically the increasing of weight 
and BMI, however, is meaningless (p=0.09) and (p=0.08). 
There is a difference of weight in series of measurement, 
particularly after the 12th month (Repeated test ANOVA 
p=0.024). Even though there is no difference in BMI average, 
there is a difference in subject's proportion based on BMI 
categories before and after Monoplant® placement (Marginal 
homogeneity test p=0.046). The increasing of levonorgestrel 
level occurs in the 6th month and subsequently followed by 
the increase of BMI in the 12th month.
Conclusions: There is a tendency of increasing weight and 
BMI in Monoplant® users, specifically after one year despite 
statistically insignificant.
Keywords: levonorgestrel, monoplant®, weight, body mass 
index.
Abstrak
Tujuan: Untuk mengetahui perubahan berat badan dan 
indeks massa tubuh pada akseptor implan levonorgestrel 
satu batang (Monoplant®).
Metode: Studi deskriptif dengan desain potong lintang 
mengambil data perubahan BB dan IMT diperoleh dari 
pengukuran serial yang tercatat dalam rekam medis pasien 
selama tiga tahun pemasangan Monoplant® di Klinik Raden 
Saleh, Jakarta. Penelitian ini merupakan bagian dari suatu 
penelitian uji klinis fase 2 yang lebih besar.
Hasil: Dari 21 subjek penelitian ini, didapatkan rerata 
BB dan IMT sebelum dan setelah 3 tahun pemasangan 
Monoplant®yakni 53,1 (SB 11,0)  kg dan 22,4 (SB 4,5) kg/
m2, serta 54,8 (SB 9,4) kg dan 23,1 (SB 3,9) kg/m2. Meskipun 
ada kecenderungan naik, tetapi secara statistik kenaikan BB 
dan IMT tersebut tidak bermakna (p=0,09) dan (p=0,08). 
Terdapat perbedaan berat badan dalam pengukuran serial, 
terutama setelah bulan ke-12 (Uji repeated ANOVA p=0,024). 
Walaupun tidak terdapat perbedaan rerata IMT, terdapat 
perbedaan proporsi subjek berdasarkan kategori IMT 
sebelum dan setelah pemasangan Monoplant® (Uji Marginal 
homogeinity p=0,046). Peningkatan kadar levonorgestrel 
terjadi pada bulan ke-6 yang kemudian diikuti oleh kenaikan 
IMT pada bulan ke-12.
Kesimpulan: Terdapat kecenderungan peningkatan BB 
dan IMT pengguna Monoplant®, khususnya setelah satu 
tahunmeskipun secara statistik tidak bermakna.
Kata kunci: berat badan, indeks massa tubuh, levonorgestrel, 
monoplant®.
increase in BMI more than 10% of baseline BMI 
prior installation. Populations in China who use 
Norplant® was experiencing 0.8 kg weight gain in 
the first year and gained 3.1 kg more in the fourth 
year, in line with the findings in the population of 
New York.11,12In contrast with the finding, there 
were no differences in body weight after one year 
of using levonorgestrel implants.13 Another study 
in the UK found that around 5% of users decided 
not to continue the implant because the weight 
gains issue. 11
This concern about body weight can prevent 
the continuation of the use of contraceptives and 
lead to discontinuation of the use at the beginning. 
From those various studies, the researcher wanted 
to know the purpose of Monoplant®, is there any 
increasing of weight and BMI and the relationship 
between the levels of levonorgestrel with the 
change, so that it can be used as the basic data 
in considering contraceptives for family planning 
acceptors in Indonesia.
THEORETICAL OVERVIEW
Implants are one of the most effective methods 
of contraceptives that are available. The implant 
consists of a silicone rod for releasing progestin 
into the woman's body from its insertion under 
the skin through a minor surgical process. The 
implant is safe, effective and it can be used for 
long term. The period of duration of protection 
depends on the specific progestin and the type 
of polymer implants.14-16 Implant containing 
levonorgestrel can prevent pregnancy in several 
ways, including to prevent ovulation, thicken the 
cervical mucus and reduces the thickness of the 
endometrium. 15,16
Progestin is a synthetic compound that mimics 
the effects of natural progesterone but has a 
slightly different chemical structure. This progestin 
effect interacts not only with the progesterone 
receptor but also with other steroid hormone 
receptors that are androgen receptor, estrogen 
or glucocorticoid mineralocorticoid. All of the 
progestin would bind the progesterone receptor, 
and it has an effect on the endometrium, but 
each type of progestin will have its own profile 
against the other targets. 16,17
Norgestrel is a progestin hormone that is a 
part of a group of 19-nortestoteron which has 
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INTRODUCTION
Indonesia is a developing country that has 
many problems, including the high rate of 
population growth, making it challenging to create 
the improvement of public welfare distribution. 
Survey results from Indonesian Demographic and 
Health (IDHS) in 2007 showed a stagnation of 
family planning programs that can be seen from 
the low increase in the contraceptive prevalence 
rate of 60.3% in the period 1997-2003 to 61.4% 
2003-2007. By creating the nation's contraception 
that is comfortable, and affordable, hopefully, it 
can be accepted and widely used as a method 
of contraceptive choice for family planning 
acceptors in Indonesia. 1-4
One of the contraceptives in Indonesia is an 
implant that can be used for a long term, it is highly 
effective and reversible, known as implantable 
contraceptives implant contraception or Alat 
Kontrasepsi Bawah Kulit (AKBK) in Indonesia. 
These implants have been widely used in the world 
by millions of women over the last three decades. 
In comparison with another contraceptive, the 
implant has the lowest failure rate in the first year 
of use. 5-7
Norplant® is a contraceptive implant used in 
Indonesia; it was studied for the first time in 1981 
and had been approved its use by the Ministry of 
Health in 1986. The birth control implant consists 
of a package of six capsules containing the active 
ingredient of levonorgestrel(LNG). 8,9 Nowadays, 
Indonesia has developed Monoplant®; it is an 
implant comprising the same hormones with 
Norplant® with only single rod packaging. It is 
expected that Monoplant® can be one of more 
desirable contraceptives for family planning 
acceptors.
In society, some complaints in selecting 
contraceptives are associated with the side effects 
of its use. One of the concerns from this study is 
about the weight gain associated with the use of 
hormonal contraceptives. The side effects usually 
occur in the early month of use. 10 There is no 
study of weight change during use Norplant® in 
Indonesia until now. From the previous studies 
on the use of other contraceptive methods, 
etonogestrel, in the United States, 12% of the 
users complained about weight change, Croxato 
et al found 20% of its users experienced an 
a mixture of isomers dextrorotation and levoro-
tary. Dextrorotation is known as d-norgestrel 
and levorotary is known as l-norgestrel, namely 
levonorgestrel. From 19-nortestosterone de-
rivative directly binds to the receptor, namely 
levonorgestrel and norethindrone, whereas des-
ogestrel and etonogestrel require bioactivating in 
the liver before becoming an active metabolite.16 
LNG is a hormone that can be active biologically 
for the anti-fertility effectsand biologically active 
progestin synthesis if given subcutaneously, there 
is no effect on the liver, and its bioavailability is 
almost 100 percent.17-19
LNG is a progestin agonist that has more 
powerful androgen agonist than other types 
and has no anti mineralocorticoid effect. 
Progesterone receptor is generally binding in 
reproductive tissues, but unfavourable effects 
have much correlation with receptors in tissues 
non-reproduction. The increase of blood 
pressure, weight gain and risk of cardiovascular 
disease caused by a lack of receptor antagonist 
of receptor mineralocorticoid in the intestine 
and kidney. Aldosterone which is a ligand of 
mineralocorticoid receptor functioning in the 
absorption of sodium in the distal renal tubular. 
It is useful for the regulation of blood pressure, 
improving and preventing the retention of 
sodium, increasing the retention of aldosterone 
in a secondary way to trigger H2O osmotic 
retention so that the extracellular fluid volume 
increases and causes weight gain. 20-22
Monoplant® is the latest generation of a 
contraceptive implant consisting of a single rod 
implant that has 43 mm length, 2.5 mm diameter 
and containing 160 mg of LNG. This single rod 
system is projected to have efficacy for up to three 
years. Monoplant® is applied to the acceptor at 
Raden Saleh Clinic in Jakarta for approximately 
three years.
Weight is the amount of protein, fat, water 
and bone in the body that can be measured in 
kilograms. In normal adults, there is an increasing 
trend of accumulation of fat with age, along with 
the decreasing of muscle protein. Such changes 
can be seen by determining body fat or fat-free 
mass. Weight can only be used to measure the 
nutritional status of the subject without oedema, 
ascites, starvation, dehydration, massive tumour 
growth because it can provide an assessment 
that is less precise in measurement.23,24
To measure the change in body weight, the 
actual weight, and the weight should be acquired. 
Intake depends on the food consumption which 
is influenced by many factors such as financial 
situation, eating habit, appetite, culture, the ability 
to consume and absorb nutrients.23-26Nutritional 
needs are also influenced by various factors 
such as infections, acute or chronic illness, fever, 
trauma, normal growth, pregnancy, rehabilitation, 
psychological stress. Nutritional status is also an 
important factor in the prediction of the main 
causes of death, including cardiovascular disease, 
hypertension, cerebrovascular, and diabetes.23-25
An evaluation of the size of the human body 
known as anthropometry to measure body 
composition can be done in order to measure the 
nutritional status.  Furthermore, to evaluate the 
nutritional status of individuals in the dimensional 
measurement and body composition, it involves 
physical measurement associated with the 
standard links with the growth or development 
of the individual, or to monitor the effects of an 
intervention on the nutritional status. 23,24,27
The Body Mass Index is a measurement widely 
used to measure the nutritional status. It has 
been validated by the measurements taken by 
body weight in kilograms and height in m2. BMI 
does not distinguish between weight associated 
with muscle and weight associated with body 
fat; in some circumstances, higher value may 
be obtained from the increase in adiposity, 
muscles or oedema. BMI has its limit because 
it does not give a picture of the distribution of 
body fat, but the validity of body mass index as 
the index of body fat percentage in adults that 
have been assessed by connecting it with a body 
mass index of obesity. 25,26This measurement 
can be an indicator of body fat used in a simple, 
inexpensive and noninvasive way, becoming 
good measurement methods for health screening 
and risk. BMI measurement is influenced by some 
factors such as age, sex, ethnicity and muscle 
mass. 27,28
In the population groups in Asia-Pacific region 
as shown in Table 1. Has body mass index value< 
18,5 kg/m2 for underweight, 18.5 – 22.9 kg/m2 for 
normalweight, ≥ 23 kg/m2 for overweight and ≥ 
25 kg/m2 for obesity. There is an increasing risk of 
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morbidity from type II diabetes and hypertension 
in body mass index between 23 to 24.9 kg/m2.29
Weight gain is one of the factors that 
influence the selection of contraceptives or to 
continue to use contraceptives.30 The weight gain 
can be caused by several factors: fluid retention 
increased muscle mass or body fat accumulation. 
LNG is a synthetic progestin that has a chemical 
derivative testosterone structure that has the most 
powerful androgenic effects. Mineralocorticoid's 
effect on LNG acceptor can increase body weight 
through fluid retention due to stimulation of the 
renin-angiotensin mechanism. Earlier research 
in 2004 suggested that an increase in weight 
associated with the accumulations of body fat. 
The measurement of body mass index is done to 
measure these indicators objectively.31
Based on Cochrane systematic review, there 
was a slight weight gain on users of progestin-only 
contraceptive as one of side effects complained 
of by the patient. The weight gain is estimated 
at only about 2 kg in the first year of use. But 
the systemic review had a difficulty relating to 
the lack of prospective studies with good quality 
because the existing research just reported 
subjective complaints of weight gain generally 
without objective evidence of the measurement 
before and after monitoring. 31
METHODS
This study is part of a larger study conducted 
by Gunardi ER. The study aims to determine 
the effectiveness of a single rod implant 
levonorgestrel through LNG levels measurement 
on the subject of reproductive age (20-40 
years) with three years of use. The study was a 
phase 2 clinical test. While this study is a cross-
sectional descriptive study that used Gunardi 
ER’s secondary data research to determine the 
profile of changes in subject’s body weight and 
body mass index after three years of LNG single 
rod implementation.32
Data collection was done through medical 
records of patients at the Raden Saleh Polyclinic. 
The target population is women who use single 
rodlevonorgestrel implants. Population achieved 
was the subject of phase 2 clinical test by Gunardi 
ER. The inclusion criteria were a mother who has 
measured her maternal weight and levels of its 
levonorgestrel regularly and routinely, and those 
who had medical records that are legible and 
clear. Did not have exclusion criteria. Consecutive 
sampling was done in this research, and it was 
taking all of the acceptor subjects to be a sample 
of the data until the data are met.
The research was started by doing a preparation 
to conduct discussions with the supervisor, 
and then collect data from medical records, 
processing data with data verification, editing and 
coding and data analysis will be performed using 
SPSS (Statistical Package for the Social Sciences, 
Chicago., Inc.) version 22 with the characteristics 
descriptive data presentation of the subject 
study, weight changes over time, significant 
changes to the subject of serial measurements of 
body weight in three years, mean comparison of 
weight and BMI pairing variable before and after 
three years of Monoplant® installation, and the 
BMI data presentation as categorical data.
RESULTS
This study has successfully collected 21 medical 
records of patients who became the subject of 
phase 2 clinical test previously. Researchers then 
extract the subject characteristics data and the 
weight data and calculated BMI of all subjects. All 
of the subjects then included in this analysis.
Characteristics
Age (year), Mean (SD)
Parity (median, min-max)
1 
2
> 2 
Wants to have more children? 
Yes
No
Contraception that is used before 
Pill
Implant
Injection
AKDR
Never use any
Weight, Mean (SD)
Height, Mean (SD)
31.4 (5.6)
2 (1-5)
7
5
9
6
15
4
2
12
2
1
53.1 (11.0)
153.86 (3.6)
33.3
23.8
42.9
28.6
71.4
19.0
9.5
57.1
9.5
4.8
V %
Table 1. Characteristics of Research Subject
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The mean age of reproductive women who is the 
subject of this study was 31.4 with SD (5.6) years. 
Most of the subjects already have more than 2 
children (9 subjects, 42.9%). Furthermore, 71.4% 
of the subjects did not want more children. From 
the history of the contraceptive modalities before, 
12 subjects (57.1%) using injectable hormonal 
contraceptive before following this study as 
shown in Table 1.
The researcher found the trend change in 
the weight of all the research subjects. Prior to 
the Monoplant® installation, the average weight 
subjects were 53.1 (SD 11.0) kg. From time to 
time, there was a tendency for weight gain as 
seen in Figure 1. The biggest change occurred in 
the 12th month whereas previously (at 9th month) 
the average weight of all subjects was 53 kg, then 
changed to 55.4 kg. Mean weight in the third year 
was 54.8 (SD 9.4) kg.
ANOVA repeated test results with all of nine 
serial measurements of weight variables showed 
a significant change in the body weight during 
the three years of research period (p = 0.024). In 
particular, the results of paired-wise comparison 
of repeated ANOVA test showed significant 
differences in early weight with 12th month weight 
(p = 0.004), the 3rd month with 12th month (p = 
0.006), 6th months with 12th month (p = 0.002), 
9th month 12th month (p = 0.001) and 12th month 
with 18th month (p = 0.02).
The increasing of weight and BMI prior to 
installation and after three years of Monoplant® 
use as shown in Table 2. Shows the average 
subject weight gain was 1.7 kg.
Total of six subjects (28.6%) experienced a weight gain while only one subject (4.8%) experienced 
weight loss as shown in Table 3.
There are differences in BMI categories 
subject before and after Monoplant® installation 
(p = 0.046). From the table 4 there is a trend of 
BMI increase based on the categorization of BMI 
subject.
Figure 1. Mean weight subject from time to time during 
the three years of Monoplant® installation (n = 21)
Figure 2. Mean Subject Levonorgestrel Level from Time to 
Time with Monoplant® Installation (n=21)
Variable
Weight (kg),Mean (SD)
BMI(kg/m2),Mean (SD)
53.1 (11.0)
22.4 (4.5)
54.8 (9.4)
23.1(3.9)
0,09
0,08
Before installation After installation P-value
Table 2.The Differences between Body Weight and BMI before and after Three Years of Monoplant®Installation
Characteristics of weight change 
Gaining
Constant  
Losing
6
14
1
28.6
66.7
4.8
V %
Table 3. Subject Frequency Distribution Based on 
Weight Change
Table 4.Test Result of BMI Change Marginal Homogeneity
BMI before 
installation
Total
Underweight
Normoweight
Over-obese
2
0
0
2
2
7
0
9
0
2
8
10
4
9
8
21
0.046
BMI after installation
Total P-value
Underweight Normoweight Over-obese
 
53.1
53.4
53.1 53
55.4
54
54.6
54
54.8
body weight in kg 
Months
0
 Months
3
Months
6
Months
9
Months
12
Months
18
Months
24
Months
30
Months
36
211,1
 
160,4  
299,1
 
259,4
 
160,9
 
208,3  
month 0 month 3rd month 6th month 12th month 18th month 24th
mean levonorgestrel (pg/ml) 
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There are differences in BMI categories 
subject before and after Monoplant® installation 
(p = 0.046). From the table 4, there is a trend of 
BMI increase based on the categorization of BMI 
subject.
The levels of levonorgestrel subject of this 
study as seen in figure 2. Analysis of the correlation 
of LNG level at each measurement by weight 
found that there were negative correlation LNG 
levels on the 12th month with 12th-month weight 
(r = -0.611; p = 0.005) and BMI in the 12th month 
(r = -0.54; p = 0.016). This negative correlation 
remained visible until the 18th month with the 
acquisition of a significant negative correlation 
between the LNG levels on the 18th month with 
18th-month weight (r = -0.52; p = 0.019) and BMI 
on the 18th month (r = -0.52; p = 0.018).
DISCUSSION
The main objective of this study is to assess 
weight and BMI change of patients with a single 
rod Monoplant® implant. The main result obtained 
is a weight gain based on serial measurements, 
especially after the 12 months since installation. 
In addition, there was an increased BMI subject 
based on classification comparison of BMI 
subjects before and after Monoplant® installation.
For data distribution of research shown in 
Table 1. The obtained reproductive age who 
are the subject of this study mean was 31.4 (5.6) 
years, with the majority already have more than 
2 children (9 subjects, 42.9%) and 71, 4% of the 
subjects did not want more children. Therefore, 
we can see that from the subjects who wanted to 
use these implants expecting good contraception 
and enough to be used in the long term. For a 
history of the contraceptive modalities before, 
12 subjects (57.1%) using injectable hormonal 
contraceptive before participating in the study. 
From previous studies, it was found that the 
subjects did not use hormonal contraception 
in the last six months so it should be stricter 
in selecting their hormonal effect before 
participating in the study. 33
There was no significant change linked to 
weight and BMI numerical variables before and 
after the installation as shown in Table 1. However, 
if the observed trend of weight changes serially, 
there was a significant difference in weight before 
and after the 12th month as seen in figure 1.
In 2005 women's weight data distribution of 
the US population in 1999-2002 according to the 
CDC (in kilograms) by the age range obtained 
tendency to the addition of the average weight 
of the age range population 20-29 to 40-49 
and will tend to decline over the age range of 
50-59 years and older. This can be one of the 
data about weight gain judged by the increasing 
age. Distribution of a woman's Body Mass Index 
by the age range there was an increased but 
declined to the above age range of 60 and older. 
34 In normal adults, there is a trend of increasing 
fat accumulation along with the increasing in age 
and decreasing of muscle protein. 22
Increased weight change category as shown 
in Table 2 can be measured as an increase in 
weight change of subject 28.6% and 66.7% were 
constant. It is assessed according to research 
with the definition of the weight gain = increase 
≥ 2.3 kg weight; constant = change of less than 
2.3 kg weight; ≥ weight loss = losing of 2.3 kg of 
weight. 33 However, this study has not been able 
to show data related to several factors, especially 
factors eating habit, physical activity, lifestyle 
and psychological. 22 Those data on the subject 
is a limitation because it cannot be shown in this 
study.
Based on BMI classification of the subject 
before and after installation, there was an 
increasing number of subjects with his class 
BMI rise as shown in Table 3. BMI is a simple, 
inexpensive and noninvasive anthropometric 
measurement correlated with body fat and can 
be connected to predict morbidity on health risks 
for the screening of nutritional status to know 
the results of this research, we get an idea that 
this initial study can be generalized to a larger 
population.
BMI measurement has the limitation that 
should be considered because it does not 
distinguish between fat, muscle or bone mass 
and does not give an idea of the fat distribution 
among individuals. The average older parents 
have more body fat than younger adults and 
trained athletes may have higher BMI because of 
the increasing muscle mass. 23,27,28
Weight gain is one of important side effects 
that needs to be investigated observing from the 
previous study, body weight is one of the causes 
why women with childbearing age don’t want to 
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continue a modality of contraception. 30,35
Theoretically, weight gain can be caused 
by various factors, one of them is the use of 
contraception. The biological mechanisms 
of hormonal contraceptives increase the 
weight through their fluid retention due to 
mineralocorticoid effects of secondary process 
activates the renin-angiotensin-aldosterone. 36
Other than a side effect, there is the opinion 
that the effectiveness of the implant can be 
influenced by better nutrition condition, namely 
in overweight and obese individuals. This is due 
to the inverse relationship between the levels of 
progestin that is released by the implant with 
someone’s weight. Although there has been 
researching to prove it, but the results are still 
disputed.37The levels of etonogestrel reduced in 
obese women but does not necessarily reduce 
its effectiveness.38 However, other unwanted 
effects of factors hormonal contraceptive use 
and the incidence of overweight / obesity is 
a risk of thrombosis, cardiovascular. With the 
results of this study, it is expected to be used as a 
consideration in choosing the right contraceptive 
in the future.
The existence of a significant increase in body 
weight after Monoplant® use on the 12th month 
onwards as seen in figure 1. Weight affect the 
circulation levels of LNG itself causing the low 
concentration on the use of Norplant® and Jadelle®. 
But the constant levels are needed to prevent 
pregnancy remain unfulfilled.16Researchers have 
not been able to explain why it happened in this 
population. Until now, there has been no similar 
study that explain it. In connection with the 
pharmacokinetic Monoplant® profile, this study 
found a negative correlation between the degree 
of significant moderate levels of LNG subject, 
weight and BMI of the 12th month (weight r = 
-0.611 p = 0.005 and BMI r = -0.54 p = 0.016) and 
18th (weight r = -0.52 p = 0.019 and BMI r = -0.52 
p = 0.018). When examined from graphs 1 and 2, 
the increase levels of LNG at 6th month precede 
the weight gain of the 12th month. A negative 
correlation between weight and levels of LNG. 
Other research also found a negative correlation 
between BMI and LNG levels (r = -0.39). 39
This study also showed a significant change in 
body weight after one-year use of Monoplant®. 
Previous studies that compared the weight gain 
after the use of DMPA, levonorgestrel implants, 
or contraceptive pills showed no changes in body 
weight were significant in all three acceptors of 
contraception.40 If seen at the effect of weight 
gain after three years, the average weight gain in 
this study was 1.7 kg, the weight gain of DMPA 
users after three years of use in the study was 
5.1 kg while subjects with contraceptive pills do 
not experience significant weight gain. However, 
only 17% of the subjects who had complete 
weight data at the end of the study, there was a 
possibility of dropped out subjects when realizing 
the weight gain.41 Based on the results of this 
study, the use of Monoplant® has lighter effects 
in terms of weight gain compared to DMPA users.
The advantages of this study were the serially 
analyzed body measurement of weight and 
BMI, not just complaints by implantusers. With 
the objective measurement of body weight, it is 
expected to give more accurate picture of the side 
effects of weight gain in the female population 
of Monoplant® users in Indonesia. Moreover, 
this is the first study to evaluate changes in body 
weight and BMI Monoplant® acceptor as a single 
rod implant.
The limitations of this research are still part 
of the phase 2 clinical test studies. It is expected 
that a bigger prospective cohort study will be 
done to know the changes in nutritional status of 
Monoplant® acceptor. Recruitment of the subject 
was still a purposive sampling.
This study also has limitations that is the 
absence of data on the factors that influence 
weight gain, namely the physical activity, eating 
habits, psychological, lifestyle of the subject. It is 
expected in the future that those factors can be 
examined for a better research results. Another 
limitation in this study, is the major cause weight 
gain could not be ascertained because the scale 
of measurement using the body mass index has 
not been able to represent the composition of 
the whole body, it is expected in the future that 
the study can be done with a better diagnosis, 
for example by using bioelectrical impedance 
analysis (BIA).
CONCLUSION
There was an increase in mean body weight, 
especially after one year but not statistically 
significant. There was an increase in mean BMI 
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and the proportion became a higher category, 
but statistically it is not significant. There was a 
correlation between levels of LNG to BMI on the 
12th month and to 18th. The presence of elevated 
levels of LNG on the 6th month preceding the 
increase in BMI and body weight at month 12 
after Monoplant® installation. But theoretically, 
it cannot be concluded that the levonorgestrel 
causes the weight gain of the BMI measurement 
results.
SUGGESTION
Further study with larger sample size is required 
so that the results can be generalized to the larger 
population in Indonesia, taking confounding 
factors that influence weight gain, for example, 
eating habits, physical activity, lifestyle and 
psychological, it should be considered to use 
other evaluation tools such as bioelectrical 
impedance analysis to determine weight gain 
in more detailed view of the composition of the 
body, it is also necessary to evaluate the long-
term effects of levonorgestrel in increasing body 
weight and BMI at Monoplant® acceptor in 
Indonesia. 
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